A research collaboration has found an efficient way to expand the collective behavior of swarming microrobots: Mixing different sizes of the micron-scale ‘bots enables them to self-organize into diverse patterns that can be manipulated when a magnetic field is applied.
A novel compound, developed by College of Veterinary Medicine researchers, that has the potential to starve the bacteria that causes tuberculosis – the world’s second-leading infectious killer – is entering human clinical trials.
Through their work on the dynamics of liquid mixtures, scientists have developed a new approach to the problem of cleaning sensitive, electronic surfaces.
David Reetz, director of counseling and psychological services at the Rochester Institute of Technology, has been named Cornell’s new director of Counseling and Psychological Services; he will join Cornell in mid-December.
Hospitals have begun using “decision support tools” powered by artificial intelligence that can diagnose disease, suggest treatment or predict a surgery’s outcome.
Dr. Robert A. Harrington, a cardiologist and chair of the Department of Medicine at Stanford University, has been named the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University.
Students in the Milstein Program in Technology & Humanity spent eight weeks this summer exploring New York City and thinking deeply about the implications of technology.
A small but significant metabolic difference between human and mouse lung tumor cells has been discovered by Weill Cornell Medicine researchers, explaining a discrepancy in previous study results and pointing toward new strategies for developing cancer treatments.
Forte Protein – a new Cornell startup that grows commercial animal proteins inside agricultural plants – has joined the university’s Center for Life Science Ventures business incubator.